1)Harzard JB, Hawk WA, rite G Jr:Medullary(Solid)carcinoma of the thyroid. A clinicopathologic entity. J Clin Endocr Metab 19:152-161, 1959
2)臼井由行,越宗龍一郎,井野川英利,他:多内分泌腺腫瘍2Aの1家系.医療54:176-178,2000
3)Lloyd RV, Douglas BR, Young WF Jr.:Atlas of nontumor pathology. Endocrine diseases, First series, American Registry of Pathology and Armed Forces Institute of Pathology, Washongton DC, 2002, pp149-169
4)Saad MF, Ordonez NG, Rashid RK, et al:Medullary carcinoma of the thyroid a study of the clinical features and prognostic factors in 161 patients. Medicine 63:319-342, 1984
5)高見 博,亀山香織,細田泰弘:MEN2型の集計:第28回甲状腺外科検討会アンケート集計結果より.内分泌外科13:1-6,1996
6)宮内 昭,高井新一郎,隈 寛二:術式治療法をどうするか―私はこうしてる:―髄様癌.臨外11:593-598,1986
7)Stepanas AV, Samaan NA, Hill CS Jr, Hickey RC:Medullary thyroid carcinoma:importance of serial serum calcitonin measurements. Cancer 43:825-837, 1979
8)Wohlk N, Cote GJ, Bugalho MM, et al:Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 81:3740-3745, 1996
9)Romei C, Elisei R, Pinchera A, et al:Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab 81:1619-1622, 1996
10)Lips CJM, Landsvater RM, Hoppener JWM, et al:Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 331:828-835, 1994
11)Wells SA Jr, Chi DD, Toshima K, et al:Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 220:237-250, 1994